leadf
logo-loader
viewImmuPharma PLC
(
AIM:IMM
)

ImmuPharma attracts first funding from US healthcare specialists

L1 Capital Global Opportunities Master Fund and Lind Global Macro Fund will receive unsecured convertible securities and associated options

ImmuPharma PLC -
ImmuPharma's lead program is Lupuzor, which is in Phase III trials as a treatment for lupus

ImmuPharma PLC (LON:IMM), the AIM-listed drug development group, has arranged funding of up to US$6.3mln through two specialist US healthcare investors.

The money will come from an issue of unsecured convertible securities and associated options to L1 Capital Global Opportunities Master Fund and Lind Global Macro Fund.

WATCH: Immupharma chairman 'delighted' with first significant investment from specialist US funds

In a statement, Tim McCarthy, ImmuPharma's chairman said: “This is the first significant investment from specialist US healthcare funds and illustrates the attention we are now receiving from knowledgeable global investors.

“It particularly exemplifies the strengthened investment thesis of ImmuPharma, as we continue to strengthen and progress our recently expanded development pipeline to value inflexion points, including Lupuzor and the partnership with Avion Pharmaceuticals, as we prepare for the start of a new international optimised Phase III trial, in lupus patients."

The cash will fund continued expansion of the company's R&D programmes, Immupahrma said, and bolster its general financial position.

ImmuPharma’s development programme includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. Its lead program is Lupuzor, which is in Phase III trials for the treatment of lupus and might have therapeutic benefit for other autoimmune diseases. 

Quick facts: ImmuPharma PLC

Follow
AIM:IMM

Price: 7.79 GBX

Market Cap: £19.49 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

ImmuPharma’s CEO, Tim McCarthy, presents commercial strategy for lupus drug...

ImmuPharma PLC (AIM:IMM)'s (LON:IMM) CEO, Tim McCarthy, presents commercial strategy for lupus drug Lupuzor™ as FDA approves PK study in advance to starting the Phase 3 trial, whilst also outlining the new Board’s plans on progressing the Company’s pipeline over the next 12 months.  The study...

on 17/8/21

2 min read